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Bioprospecting and Biopiracy in
Latin America: The Case of
Maca in Peru
Amanda J. Landon
Abstract: Bioprospecting is a popular venture in Latin America due to
the regions' high concentration of the world's biodiversity. This
activity has an impact on the native peoples living in areas with
potentially profitable plants. They can lose access to traditional plants
and extraction processes when companies patent indigenous cultivars
and knowledge. In many cases, they cannot patent their cultivars and
knowledge before others due to cultural and monetary restrictions. In
this paper, I examine the legal and cultural context surrounding the
battle over Lepidium meyenii (maca) in Peru. Pure World, Inc., a
United States pharmaceutical company, patented the extracts derived
from the plant. It sells these extracts to treat sexual dysfunction in
humans and other animals.
The pharmaceutical company also
patented the extraction technique. Indigenous peoples in Peru had
already known about the extracts, the uses for the plant, and the
extraction technique for thousands ofyears. They are suing to overturn
the patents on maca, not to claim patents on the plant for themselves
but to return the plant to their cultural domain. They have found a way
to solve their problem with biopiracy without sacrificing their cultural
values.
Introduction

Latin America is a popular destination for bioprospecting, and
has produced numerous lucrative plants, including the enola bean and
the maca plant. Companies that bioprospect do not, however, always
respect the interests and values of the indigenous peoples from whom
they gather ethnobotanical information and resources. This article
discusses biopiracy and bioprospecting in Latin America as they relate
to law, patents, and indigenous groups, focusing on the legal battle over
Lepidium meyenii (maca) in Peru. The indigenous peoples in Peru are
using strict Peruvian patent laws to return an important plant to
indigenous control without sacrificing their cultural values.
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An understanding of intellectual property rights and patents as
they apply to indigenous cultures is important for understanding the
issues surrounding biopiracy. In the United States, two types of patents
can apply to plant materials: a utility patent for nonobvious, useful,
and unique plant materials that requires users to pay royalties, and plant
variety protection that requires additional uniformity, but requires no
royalties (Brush 1993). Brush (1993) argues that applying intellectual
property rights to indigenous knowledge is difficult due to the nature of
indigenous knowledge and communities. To innovate, indigenous
communities use communal effort, referred to as collective invention,
in which members of a society freely share information that is used by
other members. In this sense, indigenous knowledge is communal or
public knowledge. In addition, due to trading knowledge between
groups, it is difficult to define the group or groups that own the
knowledge. If one indigenous group patents part of its communal
knowledge and resources, other indigenous groups that also rely on the
knowledge and resources are left out (Brush 1999). Even if indigenous
groups could find an equitable way to draw a line between who does
and who does not own certain parts of indigenous knowledge, patents
are not always compatible with the community-centered values of
indigenous groups. If indigenous groups do not patent their plant
resources, allowing corporations such as pharmaceutical companies to
patent part or all of an indigenous cultivar legitimizes an act that is
otherwise culturally reprehensible (Brush 1999). Indigenous groups in
Peru object to the patents that PureWorld, Inc. has on maca for both
economic and cultural reasons (see case study).
Bioprospecting refers to acquiring biological resources that
represent the property of another group of people without a contract
that assures compensation for access to that genetic resource. This
notion assumes that the resource is property in the sense that an
individual or group of individuals literally owns the resource. Some of
these resources originated in open exchange systems in which many
individuals from multiple groups contributed to the cultivar and
associated knowledge, so no easily distinguished group claims
ownership (Brush 1999).
Bioprospecting, in contrast, requires
reciprocity. The researcher provides both short-term and long-term
payments for access to the genetic resources (Brush 1999).
The Global Exchange, a group that follows the issues facing
indigenous peoples in Mexico, also brings up the problems associated
with what they refer to as the "privatization of life" (2001:3). The
privatization of biological materials is a concern because it can result in
a monopoly over certain natural resources, prevent indigenous peoples
from being able to obtain food, water and health care, as well as require
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indigenous peoples to pay for traditional medicines and foods that used
to belong to them. In this sense, biopiracy also includes corporate
restriction on the traditional lives of indigenous peoples by way of
limiting their access to the natural resources that they have traditionally
used for various purposes. The effects are twofold: indigenous peoples
can be denied compensation for their knowledge and be charged to use
the resources the companies discovered using indigenous knowledge.

Biodiversity, Indigenous Peoples, and Trade
The Earth's biodiversity "hot spots" tend to be concentrated in
the tropics (Kleidon & Mooney 2000). Areas with high biodiversity
also tend to be in countries with the highest poverty levels, especially
with regard to those living in rural areas. This correlation holds true in
Latin America where tropical rainforests entice many pharmaceutical
companies hoping to make a profit from plant extracts, as well as a
region with a large poor rural population (Bierer et. al 2006). The
companies wishing to gain access to economically useful plants and
animals must, then, look to biodiverse countries and the people who
have experience with the plants to maximize their success in
bioprospecting ventures. The North American Free Trade Agreement
(NAFTA), the Rio Convention on Biological Diversity, and the
Marrakech Agreement are international agreements that affect
bioprospecting and trade in Latin America.
NAFTA removed trade barriers between Mexico, the United
States, and Canada (United States Trade Representative 1993). In
summary, the agreement reduces or eliminates tariffs on NAFTA
goods, defines goods covered by NAFT A and sets up guidelines for
how much of said products must be made out of materials from
NAFT A countries. The majority of the document consists of lists of
these items and under which category each falls, as well as definitions
of items. Annex VII deals with these definitions in relation to Mexico.
Pharmaceutical products, including some raw materials from which the
pharmaceuticals are extracted, are covered in the agreement. This
means that medicinal plants that were found in Mexico and are being
used by pharmaceutical companies in the United States and Canada are
covered under NAFT A and are not subject to protectionist tariffs
(United States Trade Representative 1993).
NAFT A operates at the governmental level, not between the
individuals making the transaction. While the United States, Canada
and Mexico receive some compensation for the resources that are taken
out of their countries, the individuals who originally discovered the
resources may be left out. As a result of the agreement, pharmaceutical
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companies use indigenous knowledge to find plant products to patent
and are not legally required to compensate them.
Numerous countries, including the United States and Peru,
signed the second two agreements. The Rio Convention on Biological
Diversity of 1992, signed by 162 countries, gives states the right to
sovereign control over their genetic resources. Each state determines
who has access to the genetic resources and what sort of compensation
those granted access must provide in return (Kadidal 1993). The
Marrakech Agreement, signed by members of the World Trade
Organization, includes a section that deals with intellectual property
rights called the Agreement on Trade-Related Aspects of Intellectual
Property Rights (TRIPS). The agreement allows countries to declare
that certain objects cannot be patented in order to prevent commercial
exploitation. These objects include plant and animal life (World Trade
Organization 1994). These agreements are also between governments,
not individuals or groups within the countries. Peru passed laws
regarding patents and biological diversity that protect Peruvian plants
from patents. These laws are helping indigenous peoples in the country
protect indigenous plant cultivars.
Biopiracy, Law, and the Patent System

Businesses, which usually operate on a utilitarian and legal
ethical system (meaning ethics are based on that which is legal and is
considered most useful to themselves and possibly others) see putting
patents on parts of life forms and derivatives of indigenous knowledge
as justifiable. Since patents are temporary, the business will not hold a
monopoly over the plant product forever.
Businesses may use
indigenous knowledge to narrow down which plants to use, but they
see their role as adding to incomplete, communal knowledge, which is
seen as public rather than private (Chen 2004). Businesses will patent
extraction techniques, the chemical reasoning behind the utility of a
plant and sometimes parts of the plant itself that were uncovered in a
laboratory. They see processing the plant in the lab as creating
something new and patentable (Gollin 1999).
Patents are expensive, although precise cost depends on how
many claims are made in the patent application, which fees apply to the
patent, whether the patent is to be national or international, and other
conditions. The price ranges from hundreds to thousands of dollars
(United States Patent and Trademark Office 2006). This financial
barrier alone prevents most indigenous peoples in Latin America from
patenting their own knowledge, extraction techniques, and cultivars to
protect against utilization by other groups (Global Exchange 2001).
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Indigenous cultural values can also prevent these groups from
obtaining patents. Patents are immoral in some indigenous value
systems due to the groups' focus on communal rather than private
ownership (Global Exchange 2001). In this situation, it would be
difficult for a company to compensate the peoples from which it gained
information about plants since this exchange could be seen as an
attempt to buy their knowledge of the plants. This is a problem that
comes from differences in cultural values, especially those regarding
ownership. Illegal biopiracy usually deals with what occurs between
companies and states, leaving out laws to protect the knowledge of
indigenous peoples. Since indigenous knowledge is communal, it is
usually viewed as public domain by law. This situation can create
problems for the indigenous peoples when companies interview them
for information about plants. There is no way for them to protect their
knowledge, barring legal action if the company is backed by an entity
with more power, such as the Peruvian government in the case of the
maca patents (see case study).
Indigenous peoples are not only left open to offense from the
patent system. They can also lose their ability to sell their own plants,
as was the case with the enola bean in Mexico. POD-NERS, a United
States seed company, patented the bean and later sued Mexican
companies that were selling the bean in the United States (Global
Exchange 2001). The patent system can also lead to indigenous
cultivars being patented by companies that neither cultivated nor
greatly altered the plant (Gept 2004). Indigenous peoples have been
prevented from replanting and selling their own seeds as a result of the
patent system.
Legally, there are grave consequences for companies that
break the law in regard to biopiracy. According to attorney Michael A.
Gollin (1999), companies that violate biopiracy laws can: have their
patents revoked, lose the profits that they gained from the illegal patent,
be prohibited from collecting future samples, and face jail time.
Legally defined, biopiracy refers to failing to obtain permission to
collect samples, failing to disclose one's motivations in collecting
samples, failing to follow national laws, or failing to follow the
company's self-regulatory guidelines. Left out are widespread laws
protecting indigenous peoples' intellectual and material property rights.
Patent laws do not cover indigenous communal knowledge
since it is seen as old, public domain knowledge. Private knowledge is
covered, but such knowledge must be new and based on a discovery or
innovation. Since indigenous peoples do not have the finances to
patent the plants themselves, companies are generally free to do so
when they find something commercially useful. They can also patent
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extraction techniques and applications of the plant or parts of the plant
since they have the money to do so. It is the immoral rather than the
illegal biopiracy with which organizations such as Global Exchange, a
group that tracks instances and effects of biopiracy in Mexico, are
concerned.
Some companies and countries are, however, taking steps to
make bioprospecting a more equitable venture.
Shaman
Pharmaceuticals acknowledges the contribution of indigenous
knowledge to the company's bioprospecting success. The
pharmaceutical company claims that 75% of their pharmaceutical
products were found thanks to the help of indigenous peoples (Bierer et
al. 2006). Shaman Pharmaceuticals believes that it has found a way to
fairly compensate the indigenous peoples with whom they work. The
company argues that, since years can pass before one even knows
whether or not a new drug will make a profit, both immediate and long
term forms of compensation are necessary. In the short term, they have
assisted communities with their health needs by setting up clinics. In
the long term, they plan to give part of their profits to the communities
and countries from which they have acquired plants (Bierer et al. 2006).
Some countries, such as Costa Rica, have found a way to
arrange for some of the money from bioprospecting ventures go to the
indigenous peoples who live in the areas where the searches have
occurred. According to Costa Rica's Biodiversity Law, indigenous
knowledge is included in the definition of Costa Rican biodiversity (La
Asamblea Legislativa de la Republica de Costa Rica 1998). Prior
informed consent must be given before the initiation of any
bioprospecting venture to all involved, including the indigenous
peoples of the area. Companies wishing to go bioprospecting must
purchase a permit in addition to allocating 10% of their research budget
and as much as 50% of bonuses to the Costa Rican government for the
National System of Conservation Areas or the indigenous peoples
and/or private owners on whose property the specimens were found.
The companies may be required to pay additional money to the
government in the future to compensate for anything they gain by using
Costa Rica's biodiversity (La Asamblea Legislativa de la Republica de
Costa Rica 1998).
Merck, INBio, and the Costa Rican government reached a deal
that fulfills this law. Merck pays INBio money to collect samples in
Costa Rica. Merck then pays royalties to INBio for money it makes
from developing the samples into drugs. Fifty percent of the royalties
gained by INBio go to the Costa Rican government for projects related
to biodiversity and conservation (Coughlin 1993).
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Maca in Peru, a Case Study
Indigenous peoples are not without options. La lniciativa
para fa Prevencion de fa Biopirateria en Peru, a Peruvian legal group,
is aiding the indigenous peoples there, mostly Quechua and Aymani
speaking peoples, to revoke the patents held on one of their traditional
medicinal and food plants, maca (Lepidium meyenii) (Comision
Nacional contra la Biopirateria 2005). The following case study
explores the Peruvian legal setting and maca patents, as well as the
reactions of the Peruvian government and indigenous peoples. The
indigenous peoples of Peru are using Peruvian law to their advantage in
order to overturn the patents and to avoid having to define who owns
maca.
Peru's General Environmental Law (No. 28611) establishes
the rules and regulations related to the biodiversity of the country, as
well as the responsibilities of citizens in relation to the law. One part of
this law specifically provides for the rights of indigenous peoples and
traditional communities with regard to their cultures, knowledge, and
ways of life (Legislative Branch of the Republic of Peru 2005).
There are currently four main patents held on parts of the
maca plant by PureWorld, Inc. In one US patent, PureWorld, Inc.
claims the right to the cellulose-free version of the same extract used by
indigenous peoples in the Andes. They also claim the extraction
technique. Indigenous use of the plant is mentioned briefly in the
description section of the patent (Zheng et al. 2001). In another US
patent, the company claims more maca extracts, the way in which these
extracts are used to treat sexual dysfunction in animals (including
humans), and how the drug is administered to animals (Zheng et al.
2002). The company claims several more extracts and the methods
with which to obtain the extracts in a third patent (Zheng et al. 2003).
In the final patent, the company patents claims rights to several more
extracts used as treatments for different forms of cancer. This
particular patent includes a comparatively extensive section of
background information about common indigenous uses of the maca
plant, including use as a highly nutritional food source and effective
medicine (Cui et al. 2005).
The government of Peru recognizes that patents are important
tools for businesses in their quest for discoveries, innovations, and
profits. The Delegation of Peru (2003) at the Geneva Convention
expressed its views that biopiracy should be dealt with in political
rather than legal terms since the law generally addresses companies, the
government, and individuals rather than communities such as the
indigenous communities. According to Peruvian law, patents cannot be
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held on parts of plants, including extracts, since neither invention nor
creative action is involved. Patents including extracts of biological
origin, such as maca extracts, or including indigenous knowledge, are
not recognized in Peru (Legislative Branch of the Republic of Peru).
In the same paper, the Delegation of Peru (2003)
acknowledges that maca is a plant that has been cultivated over
thousands of years by the indigenous people of Peru. They cite
historical references as far back as the 1500s to show that the plant was
known outside of the indigenous community, as well, for a long time.
They also cite examples that show that the indigenous peoples and
traditional communities that have been using maca for generations and
have known about at least some of the components of the root that the
company has patented. The rest of the components were previously
described in a bachelor's thesis by a student at a Peru university
(Roldan 1961, Delegation of Peru 2003). In the patents, the company
acknowledges that indigenous peoples had prior knowledge of the
plant's medicinal use in helping animals with sexual dysfunction. In
the government of Peru's view, PureWorld, Inc. has discovered nothing
and should not hold patents over maca.
The indigenous peoples of Peru now face a problem relating to
the demand for maca worldwide, which requires so much of the plant
to be exported. In addition, PureWorld, Inc. has patented an extraction
technique that is very close to that employed by the indigenous peoples
using the plant; the only difference is the final step in which the
company removes the cellulose from the extract (ETC Group 2002).
Indigenous peoples are also aware that they knew of the many uses of
maca before PureWorld, Inc. patented anything related to maca.
PureWorld, Inc. has not discovered anything that their traditional
communities did not already know.
They hope to revoke the
PureWorld, Inc. patents rather than demand royalties from the
company's profits (Trade Environment Database 2006).
Conclusion

With the backing of the Peruvian government, the indigenous
peoples living in the Andes are fighting to revoke PureWorld, Inc.'s
patent rights, at least in Peru if not in the United States. The
indigenous groups are not going to claim patent ownership on the
maca. They avoid designating which groups have the right to the plant
by keeping it in the realm of communal knowledge and cultural
property. They are not sacrificing their values by claiming individual
ownership of the plant, either. The indigenous peoples have found a
solution that is suitable for them in their cultural context. The laws of
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the two countries involved differ in relation to patents, but without
Peru's recognition of the US patents held by PureWorld, Inc., the
indigenous and traditional farmers will be allowed to continue using
their traditional medicine and selling their extracts outside of the
United States.
This case study shows that, in spite of the interests of
businesses that bioprospect conflicting with indigenous interests,
indigenous peoples can protect communal knowledge and cultivars on
indigenous terms. They do not have to bow to national or international
pressure to either patent their knowledge and cultivars or accept
royalties from others who patent them. TRIPS and the Convention on
Biological Diversity give countries the right to sovereign control over
their plant resources and patents, allowing countries to pass legislation
that protects indigenous resources. It is vital that indigenous peoples
have legal recognition, as they do in Peru, to protect their culture from
exploitation.
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